Has Eli Lilly Stock Peaked?
Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion. For a while, it looked like it might be on track to be the first healthcare company to top a $1 trillion valuation, perhaps as early as this year.But over the past three months, the stock has fallen by 14% as the recent election results don't appear to be inspiring much enthusiasm around the business. Fears of heightened oversight in the industry could weigh on not just Eli Lilly, but healthcare stocks as a whole. Plus, there is also the concern that the stock's high valuation may finally be catching up to it.Has Eli Lilly's stock indeed peaked, and could this be the start of a much broader sell-off, or is now a potentially good time to add the healthcare giant to your portfolio?Continue readingWeiter zum vollständigen Artikel bei MotleyFool
Ausgewählte Hebelprodukte auf Eli Lilly
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Eli Lilly
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: MotleyFool
Nachrichten zu Eli Lilly
Analysen zu Eli Lilly
Datum | Rating | Analyst | |
---|---|---|---|
20.12.2024 | Eli Lilly Buy | Jefferies & Company Inc. | |
31.10.2024 | Eli Lilly Buy | Jefferies & Company Inc. | |
13.02.2024 | Eli Lilly and Buy | Jefferies & Company Inc. | |
05.10.2018 | Eli Lilly and Outperform | BMO Capital Markets | |
25.07.2018 | Eli Lilly and Neutral | Goldman Sachs Group Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
20.12.2024 | Eli Lilly Buy | Jefferies & Company Inc. | |
31.10.2024 | Eli Lilly Buy | Jefferies & Company Inc. | |
13.02.2024 | Eli Lilly and Buy | Jefferies & Company Inc. | |
05.10.2018 | Eli Lilly and Outperform | BMO Capital Markets | |
08.06.2018 | Eli Lilly and Overweight | Cantor Fitzgerald |
Datum | Rating | Analyst | |
---|---|---|---|
25.07.2018 | Eli Lilly and Neutral | Goldman Sachs Group Inc. | |
27.04.2017 | Eli Lilly and Hold | Argus Research Company | |
20.03.2017 | Eli Lilly and Neutral | UBS AG | |
22.07.2015 | Eli Lilly and Equal Weight | Barclays Capital | |
08.01.2015 | Eli Lilly and Hold | Deutsche Bank AG |
Datum | Rating | Analyst | |
---|---|---|---|
21.04.2017 | Eli Lilly and Underperform | BMO Capital Markets | |
15.10.2012 | Eli Lilly and underperform | Jefferies & Company Inc. | |
30.06.2010 | Eli Lilly Ersteinschätzung | Soleil Securities Group, Inc. | |
14.12.2009 | Eli Lilly sell | Goldman Sachs Group Inc. | |
02.12.2009 | Eli Lilly sell | Goldman Sachs Group Inc. |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Eli Lilly nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen